111 results about "Malabsorption" patented technology

The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from Candida cylindracea, alone or in combination with amylase or amyloglucosidase, protease and/or lactase. Furthermore, the invention discloses methods for treating pancreatic enzyme insufficiency comprising administering compositions to patients in need thereof.

Methods and apparatus for the endoluminal revision of previously performed obesity procedures which have failed are described. One or more endoluminal instruments may be advanced per-orally into the previously formed failed pouch where a number of different procedures can be performed. One or more tissue folds can be formed and secured to reduce the size of the pouch, or the stoma connecting the pouch to the intestinal tract can be reduced in size using endoluminally deployed tissue anchors. These procedures can be performed entirely from within the pouch lumen or upon the exterior surface of the pouch via transgastric entry of the instruments into the peritoneal cavity of a patient. Alternatively, the interior tissue within the pouch can be injured or sclerosed to shrink the pouch lumen. In another alterative, a length of the Roux limb can be shortened endoluminally to create a malabsorptive region.

Method and apparatus for disinfecting and/or sterilizing a root canal system by targeting the water content of disease and debris in the canals. The laser technique of employs a frequency of the wavelength emissions between about 930 to about 1065 nanometers with an optimum of 980 nm. This range of wavelengths targets the water content of tissue cells and pathogens as well as any residual organic debris in water within the root canal system after its preparation while being poorly absorbed by the surrounding dentin. The selection of the optimum wavelength produces significant effects generating and advancing treatment to the targeted aqueous environments. This is due to the rapid energy absorption by the water and the subsequent creation of gas bubbles, liberation of heat and subsequent propulsion of waves of heat and gas that impact along the canal walls and ramifications resulting in an enhanced bacterial kill and cleaning of the canal walls and ramifications. No dyes or other additives are necessary to enhance the effectiveness of the laser kill of bacteria, etc.

The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing, or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose or carboxymethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.

A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

A method for inducing malabsorption in a small intestine of a patient may involve advancing a portion of a catheter into the patient's small intestine and expanding a portion of the catheter to apply force to the small intestine's inner wall to modify mucosal villi and/or crypts. The method for causing weight loss in a patient may also involve dilating at least a portion of the patient's small intestine to modify mucosal villi and/or crypts, destroying mucosal villi and/or crypts of the patient's small intestine using a combined coaxial and radial catheterization of the intestine, or isolating a length of the patient's small intestine and delivering a substance to the isolated length to destroy mucosal villi and/or crypts.

Disclosed is a method and composition for nutritional compositions containing -glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome/Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, -glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, -glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.

A human glucagon associated peptide-2 analog Pro-Pro-h[Gly2]GLP-2(1-35) for treating the short bowel syndrome and malabsorption of stomach and intestine is prepared through configuring genetic engineering bacterium for effective expression of Pro- Pro-h[Gly2]GLP-2(1-35) in colibacillus cell, splitting, washing, dissolving urea, depositing in alcohol, separating fusion protein, hydrolyzing it, chromatography by DEAE-52 column, separating by HPLC, and freeze drying.

The present invention relates to novel strains of avian reovirus that were isolated from severe cases of Runting Stunting Syndrome in young broiler chickens in southeast United States. The invention is directed to avian reoviruses that impair digestion in poultry, diagnostic assays using nucleotide- or amino acid-specific components of such viruses, and to vaccines that protect chickens from disease caused by such viruses. Nucleotide sequences for the SI gene, encoding the sigma C minor outer capsid protein, were amplified, and the nucleotide and predicted amino acid sequences were compared with sequences from other recently isolated reovirus field isolates and vaccine strains. Antigenic and molecular characterization of the newly isolated reoviruses revealed a lack of homogeneity with current U.S. isolates, with less than 60% percent amino acid similarity across the sigma C protein. Sequence comparisons with previously reported malabsorption isolates from Europe and Asia revealed a higher amino acid similarity, approaching 80%.

Disclosed are nutritional products comprising pea protein hydrolysates as a primary or sole source of protein. The nutritional products include nutritional liquids, powders, bars, and other food products, wherein the resulting nutritional products are physically stable over shelf life and provide favorable organoleptic properties. These nutritional products may be used as a nutritional source for individuals who are intolerant and/or allergic to cow milk proteins and soy proteins and/or who have malabsorption, maldigestion, or other gastroinstestinal conditions.

Provided herein are balloon systems and related methods for the treatment of obesity. The system includes a trans-abdominal gastric cannula and size-varying balloons that, with the assistance of the cannula(s) and anchors, are specially positioned and anchored to the gastric wall. The size-varying balloon may have an annulus that in combination with reliable and precise balloon positioning, minimizes the risk of gastric obstruction during use. A malabsorption sleeve may be positioned in the small intestine to further restrict caloric intake through the small intestine. The specially-configured gastric cannula provides a platform for accessing the gastric environment that facilitates precise handling, manipulation, and placement of balloons, including an annular-shaped balloon, in the gastric environment, including by balloon anchors connecting the balloon wall to the lumen-facing stomach wall.

Disclosed herein is an aqueous emulsion of alpha-tocopherol and preferably other forms of vitamin E, coenzyme Q10, beta-carotene, vitamin D, and vitamin K useful for treating complications of cystic fibrosis. The aqueous emulsion improves malabsorption and immunity against infection, and reduces oxidative stress and respiratory complications in cystic fibrosis.

The invention provides a combined medicine containing metformin hydrochloride and vitamin B12, which can prevent and treat diabetic peripheral neuropathy to the maximal extent, prevent metformin hydrochloride from inducing hyperhomocysteinemia, malabsorption of vitamin B12 to cause megaloblastic anemia, and treat aplastic anemia and the like.

The present invention relates to health food, and is especially preparation process of one kind of lactic acid bacteria oral liquid. The lactic acid bacteria oral liquid is prepared through mixing brown sugar, glucose, peptone, magnesium sulfate, manganese sulfate, dipotassium hydrogen phosphate and sodium chloride in certain proportion, dissolving in water and heating to sterilize; inoculating one or several of Lactobacillus casei subsp. Casei, Lactobacillus plantarum, Lactobacillus acidophilus and Bacillus coagulans; culturing at 37deg.c for 48 hr; harvesting after the pH value is lowered to about 3.6; and bacteria-free packing. The lactic acid bacteria oral liquid is brown and sour and has live lactic acid bacteria content up to 1 billion/ml. It is used in improving digestive tract function and treating gastrointestinal tract ailments.

The invention relates to a preparation comprising 5-50% by weight of Isphagula Husk; 1-20% by weight of at least one amino acid; 20-80% by weight of at least one carbohydrate and electrolytes. The preparation is for use as a therapeutical agent, such as for use in treating a state of disorder in the intestinal system of monogastric animals, including humans. A state of disorder in the intestinal system is in particular all intestinal disorders in which the epithelial layer is damaged, mostly as a result of malabsorption diarrhoea, also associated with dehydration.

The invention relates to novel vitamin compositions having increased absorption and bioavailability. Vitamin E compositions are provided, for example, having biologically significant amounts of one or more vitamin E homologues in an aqueous formulation. Also provided is a method for preparing aqueous formulations of lipophilic nutrients.

The invention provides a compound capsule containing ginseng saponin Rb1, ginseng saponin Re, radix notoginseng saponin R1, tryptophan, threonine, leucine, valine, methionine, isoleucine, phenylalanine and lysine hydrochloride, wherein the compound capsule can also contain arginine hydrochloride and/or histidine hydrochloride. The preparation method of the capsule comprises the step of preparing various amino acids and saponin into coating micro-pills respectively. The capsule has stable quality, convenient transportation, storage and use and good absorbing effect. An advanced micro-pill coating preparation technique is adopted, the amino acids, the pseudo-ginseng saponin and the ginseng saponin are respectively prepared into the coating micro-pills with various colors, the quality is more stable by respective packaging, and the absorption of an organism is further promoted, thereby retaining the high potency of the capsule. The capsule has definite curative effect and wide adaptive disease, and clinical observation shows that the capsule can effectively enhance the immunity of the organism, can quicken the healing of wounds and has a very good curative effect on various leukopenia and gastrointestinal tract malabsorption diseases.

The invention belongs to the field of agriculture, and particularly designs biological organic compound fertilizer for fragrant-flowered garlic and a preparation method thereof. The biological organic compound fertilizer for the fragrant-flowered garlic is prepared from the following components in parts by weight: 40 to 55 parts of soybean meal, 25 to 30 parts of rape seed cake, 30 to 35 parts of bran, 35 to 45 parts of herba patriniae residue, 15 to 20 parts of herba taraxaci residue, 5 to 10 parts of ramulus cinnamomi residue, 10 to 20 parts of herba portulacae residue, 5 to 8 parts of buckwheat protein, 12 to 30 parts of complex probiotics, 2 to 6 parts of surface active agent, 10 to 20 parts of active material, 1 to 2 parts of cellulase, 2 to 3 parts of trace element and a proper volume of water. The biological organic compound fertilizer for the fragrant-flowered garlic is made by carrying out a two-step fermentation process through a biological fermentation technique. The biological organic compound fertilizer for the fragrant-flowered garlic and the preparation method thereof are high in practicability; the problem of the yield reduction caused by plant diseases, insect pests and the malabsorption of nutrient substances can be effectively solved.

Said invention refers to a pharmaceutical form for selective colon delivery of drugs or bioactive molecules degraded and/or poorly absorbed in the gastrointestinal tract. The system comprises a core consisting of the active ingredient, and a protease inhibitor layer and/or an absorption enhancer layer, said core being separated from these layers by means of a polymer that swells and/or dissolves and/or is degraded when in contact with the biological fluids present in the gastro-intestinal tract; depending on the thickness of the polymeric layer, the release of the drug can be modulated with respect to the inhibitor and/or promoter.

The present disclosure generally pertains to formulations containing two or more fat-soluble vitamins, lemon oil, and zinc. Also disclosed are kits containing such formulations and methods for administering such formulations to treat malabsorption in subjects diagnosed with CF, Crohn's Disease, Colitis, Irritable Bowel Syndrome, Celiac Disease, and other like conditions.